| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Eliezer Masliah | Q28324209 |
| P2093 | author name string | Masaaki Waragai | |
| Makoto Hashimoto | |||
| Kazunari Sekiyama | |||
| Gilbert J Ho | |||
| Willie Liang | |||
| P2860 | cites work | PINK1 is selectively stabilized on impaired mitochondria to activate Parkin | Q21145802 |
| DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation | Q21146396 | ||
| DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor | Q24291490 | ||
| Tubulin seeds alpha-synuclein fibril formation | Q24291881 | ||
| Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice | Q24293070 | ||
| Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases | Q24301116 | ||
| Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy | Q24311582 | ||
| The familial Parkinsonism gene LRRK2 regulates neurite process morphology | Q24317613 | ||
| Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism | Q24321359 | ||
| Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. | Q24634577 | ||
| Genome-wide association study reveals genetic risk underlying Parkinson's disease | Q24646654 | ||
| alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies | Q24653247 | ||
| Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein | Q24655848 | ||
| Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease | Q24656668 | ||
| Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models | Q24683059 | ||
| Beta-synuclein gene alterations in dementia with Lewy bodies | Q24684579 | ||
| Differential phenotype in Parkinson's disease patients with severe versus mild GBA mutations. | Q48582719 | ||
| A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. | Q48621716 | ||
| Cortical Lewy body pathology in the diagnosis of dementia. | Q48742837 | ||
| Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. | Q48784105 | ||
| PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. | Q48788452 | ||
| Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene. | Q48831912 | ||
| Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. | Q48868609 | ||
| Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. | Q48955700 | ||
| Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. | Q49069882 | ||
| Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes. | Q49159052 | ||
| Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. | Q50283972 | ||
| Red blood cells are the major source of alpha-synuclein in blood. | Q50663283 | ||
| Hippocampal shape differences in dementia with Lewy bodies. | Q51886737 | ||
| Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. | Q51892103 | ||
| Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. | Q51926701 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| Chaperone-mediated autophagy markers in Parkinson disease brains | Q28115026 | ||
| Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide | Q28131750 | ||
| L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system | Q28185988 | ||
| Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease | Q28201316 | ||
| Glucocerebrosidase mutations in subjects with parkinsonism | Q28239212 | ||
| DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras | Q28305931 | ||
| A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies | Q28362147 | ||
| Cardiac (123)I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease | Q28366086 | ||
| Persyn, a member of the synuclein family, influences neurofilament network integrity | Q28512814 | ||
| Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. | Q28593258 | ||
| Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system | Q28594866 | ||
| Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 | ||
| The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
| Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 | ||
| DAMPs, PAMPs and alarmins: all we need to know about danger | Q29547535 | ||
| Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy | Q29614178 | ||
| Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 | ||
| Mitochondrial respiratory-chain diseases | Q29614474 | ||
| Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease | Q29614900 | ||
| Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin | Q29615684 | ||
| PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy | Q29616005 | ||
| Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein | Q30487162 | ||
| DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease | Q30493811 | ||
| A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain | Q30498862 | ||
| Proteome analysis of human substantia nigra in Parkinson's disease. | Q31125603 | ||
| Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases | Q33235503 | ||
| Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. | Q33254291 | ||
| Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies | Q33264766 | ||
| Serum proteomic profiling of dementia with Lewy bodies: diagnostic potential of SELDI-TOF MS analysis | Q33293816 | ||
| Mortalin: a protein associated with progression of Parkinson disease? | Q33316451 | ||
| Magnetic resonance imaging in lewy body dementias. | Q33517590 | ||
| Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein | Q36677512 | ||
| Disease-modifying trials in Alzheimer's disease: a European task force consensus | Q36682458 | ||
| DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers | Q36758059 | ||
| Gamma-synuclein and the progression of cancer | Q36849093 | ||
| Imaging amyloid deposition in Lewy body diseases | Q37087766 | ||
| Parkinson's disease--Part 3: Neuropsychiatric symptoms | Q37134396 | ||
| Lewy body pathology in normal elderly subjects | Q37246606 | ||
| Association of glucocerebrosidase mutations with dementia with lewy bodies | Q37379711 | ||
| The genetics of Parkinson's syndromes: a critical review | Q37472412 | ||
| Mitophagy: the latest problem for Parkinson's disease | Q37819135 | ||
| Acetylcholine and choline in cerebrospinal fluid of patients with Parkinson's disease and Huntington's chorea | Q39301729 | ||
| Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease | Q39678386 | ||
| Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease | Q39781327 | ||
| Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions | Q39806585 | ||
| Expression and role of DJ-1 in leukemia | Q39947928 | ||
| Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration | Q40071251 | ||
| Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies | Q40102845 | ||
| Synuclein activates microglia in a model of Parkinson's disease | Q40126232 | ||
| Peripheral inflammatory biomarkers and risk of Parkinson's disease | Q40171172 | ||
| Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease | Q40278884 | ||
| Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities | Q40405262 | ||
| Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. | Q40405368 | ||
| A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. | Q40601003 | ||
| Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies | Q42442006 | ||
| Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. | Q42454450 | ||
| DJ-1 degrades transthyretin and an inactive form of DJ-1 is secreted in familial amyloidotic polyneuropathy. | Q42828536 | ||
| LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß. | Q42873469 | ||
| Association of an interleukin 1B gene polymorphism (-511) with Parkinson's disease in Finnish patients | Q43074720 | ||
| Decreased cardiac MIBG uptake, its correlation with clinical symptoms in dementia with Lewy bodies | Q43274217 | ||
| Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. | Q43286528 | ||
| Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. | Q43792598 | ||
| A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration | Q43962617 | ||
| Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. | Q44091581 | ||
| Assessment of CSF homovanillic acid levels distinguishes dementia with Lewy bodies from Alzheimer's disease | Q44208377 | ||
| Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. | Q44946964 | ||
| Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. | Q45135867 | ||
| Clinical genetic analysis of Parkinson's disease in the Contursi kindred | Q45235440 | ||
| Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). | Q45970470 | ||
| Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease | Q46072995 | ||
| Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease | Q46084408 | ||
| Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease | Q46404066 | ||
| Gene expression profiling of Lewy body-bearing neurons in Parkinson's disease | Q46535275 | ||
| Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life | Q46569969 | ||
| Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease | Q46683999 | ||
| DJ-1 is essential for long-term depression at hippocampal CA1 synapses | Q46774588 | ||
| Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease | Q46836076 | ||
| Neuropathology provides clues to the pathophysiology of Gaucher disease | Q47247270 | ||
| DJ-1 colocalizes with tau inclusions: a link between parkinsonism and dementia | Q48101646 | ||
| Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology | Q48139333 | ||
| The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states | Q48155270 | ||
| Imaging beta-amyloid burden in aging and dementia. | Q48168226 | ||
| Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma | Q48183703 | ||
| Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study | Q48188599 | ||
| Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients | Q48191627 | ||
| Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease | Q48198034 | ||
| Diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease | Q48217265 | ||
| Proteomic identification of novel proteins in cortical lewy bodies | Q48227693 | ||
| Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study | Q48240563 | ||
| Plasma alpha-synuclein is decreased in subjects with Parkinson's disease | Q48295840 | ||
| The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia | Q48360091 | ||
| Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease | Q48402580 | ||
| Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. | Q48491146 | ||
| Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. | Q51976242 | ||
| CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. | Q52057738 | ||
| Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. | Q53203247 | ||
| Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. | Q53213249 | ||
| A deletion in DJ-1 and the risk of dementia--a population-based survey. | Q53265520 | ||
| Association of Parkinson disease-related protein PINK1 with Alzheimer disease and multiple sclerosis brain lesions. | Q53315139 | ||
| Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. | Q53417610 | ||
| α-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies | Q57947893 | ||
| Polymorphism in the human DJ-1 gene is not associated with sporadic dementia with Lewy bodies or Parkinson's disease | Q63194317 | ||
| Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease | Q64784256 | ||
| Influence of interleukin-1beta gene polymorphisms on age-at-onset of sporadic Parkinson's disease | Q64786053 | ||
| Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease | Q64922770 | ||
| Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridization | Q72595899 | ||
| 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies | Q73230794 | ||
| Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology | Q73551190 | ||
| Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy--unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease | Q73622229 | ||
| Dementia with Lewy bodies in an elderly Greek male due to alpha-synuclein gene mutation | Q79267853 | ||
| Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease | Q80424021 | ||
| Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease | Q80845388 | ||
| Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset | Q81147302 | ||
| Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease | Q81751463 | ||
| Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease | Q82686303 | ||
| Increased incidence of Parkinson disease among relatives of patients with Gaucher disease | Q83228051 | ||
| Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies | Q83514686 | ||
| ??? | Q64781356 | ||
| Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models | Q33552220 | ||
| Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. | Q33594388 | ||
| Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration | Q33747872 | ||
| Lysosomal degradation of alpha-synuclein in vivo. | Q33810012 | ||
| Molecular genetics of Alzheimer's disease. | Q33842568 | ||
| Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease | Q33937968 | ||
| beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor | Q34099593 | ||
| Biomarker discovery in neurodegenerative diseases: a proteomic approach. | Q34125681 | ||
| Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process | Q34148308 | ||
| Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. | Q34194714 | ||
| The neuropathology and biochemistry of frontotemporal dementia | Q34209946 | ||
| Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study | Q34287865 | ||
| Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. | Q34303003 | ||
| The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system | Q34318718 | ||
| Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein | Q34345614 | ||
| Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews | Q34365028 | ||
| Snaring the function of alpha-synuclein | Q34465204 | ||
| Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein | Q34517780 | ||
| A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers | Q34520985 | ||
| Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles | Q34541894 | ||
| Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop | Q34736093 | ||
| Gaucher disease and the synucleinopathies | Q34795306 | ||
| Aggregation and neurotoxicity of alpha-synuclein and related peptides | Q34797480 | ||
| alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity | Q34980191 | ||
| LRRK2 in Parkinson's disease and dementia with Lewy bodies | Q35214380 | ||
| Parkinsonism among Gaucher disease carriers | Q35444509 | ||
| Gaucher disease: complexity in a "simple" disorder | Q35908938 | ||
| Neurofilament proteins in neurodegenerative diseases | Q35975762 | ||
| Tau phosphorylation: physiological and pathological consequences | Q35992168 | ||
| Mechanisms of cell signaling and inflammation in Alzheimer's disease | Q36107658 | ||
| Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. | Q36226812 | ||
| CSF neurofilament proteins in the differential diagnosis of dementia | Q36227579 | ||
| Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease | Q36426239 | ||
| Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease | Q36504239 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 842475 | |
| P577 | publication date | 2011-07-03 | |
| P1433 | published in | International journal of Alzheimer's disease | Q27722932 |
| P1476 | title | Bridging molecular genetics and biomarkers in lewy body and related disorders | |
| P478 | volume | 2011 |
Search more.